If you are eligible and agree to participate in the FUSION study, you will either receive the investigational antisense medicine or placebo during the first part of the treatment period. A placebo is a substance that looks like and is taken the same way as the real potential treatment, but has no active ingredients or medical benefit. Everyone will receive the investigational antisense medicine in Part 2 of the FUSION study.
In clinical trials, a placebo is given to some participants so that the two groups-for FUSION, it is those taking the investigational antisense medicine vs. those taking the placebo-can be compared to show whether the potential treatment being studied is safe and is effective. A placebo can also help researchers determine whether certain changes during the FUSION study happen by chance or actually in response to the treatment.
